Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | HPGDS | O60760 | 2/20 | 0.36 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29859759 | 1.00 | KDM4E (0.39) | KDM4EALDH1A1LMNAGAAL3MBTL1 | |
| SCHEMBL503820 | 0.81 | EGLN1 (0.33) | KDM4EALDH1A1 | |
| SCHEMBL17520936 | 0.75 | IP6K1 (0.37) | ALDH1A1HTTCHEK1HPGDS | |
| SCHEMBL503159 | 0.75 | GABRA1 (0.31) | — | |
| SCHEMBL6846640 | 0.72 | — | — | |
| SCHEMBL5255547 | 0.70 | HPGDS (0.44) | KDM4EALDH1A1HTTCHEK1RIPK1 | |
| SCHEMBL5255546 | 0.70 | HPGDS (0.44) | KDM4EALDH1A1HTTCHEK1HPGDS | |
| SCHEMBL23731797 | 0.69 | KDM4E (0.33) | KDM4EALDH1A1GAA | |
| SCHEMBL14858833 | 0.69 | PARP1 (0.39) | KDM4EALDH1A1GAA | |
| SCHEMBL1104637 | 0.69 | PARP1 (0.43) | KDM4EALDH1A1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3661909-B1 | NOVEL SUBSTITUTED PHENYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-08-16 | — | — | EP | claimed |
| US-11274108-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | GENZYME CORPORATION (US) | 2022-03-15 | — | — | US | claimed |
| US-12331068-B2 | Compositions and methods for inhibiting CD73 | PELOTON THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20250092040-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-03-20 | — | — | US | disclosed |
| EP-3810109-B1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING CD73 | PELOTON THERAPEUTICS INC (US) | 2024-08-07 | — | — | EP | disclosed |
| US-20240239797-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-11999730-B1 | AKT1 modulators | ALTEROME THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240174667-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| US-20210253614-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CD73 | PELOTON THERAPEUTICS, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| EP-3810109-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CD73 | Peloton Therapeutics, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| CN-107849039-B | Heteroaryl substituted aminopyridine compounds | 百时美施贵宝公司 | 2020-07-03 | — | — | CN | disclosed |
| EP-3089973-A1 | HETEROARYL SUBSTITUTED NICOTINAMIDE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2016-11-09 | — | — | EP | disclosed |
| US-9475806-B2 | Complement factor B inhibitors and uses there of | NOVARTIS AG (CH) | 2016-10-25 | — | — | US | disclosed |
| US-20160024079-A1 | Complement Factor B inhibitors and uses there of | NOVARTIS AG (CH) | 2016-01-28 | — | — | US | disclosed |
| US-9169252-B2 | Heteroaryl substituted nicotinamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-27 | — | — | US | disclosed |
| WO-2015103453-A1 | HETEROARYL SUBSTITUTED NICOTINAMIDE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-09 | — | — | WO | disclosed |
| US-20150191464-A1 | HETEROARYL SUBSTITUTED NICOTINAMIDE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-09 | — | — | US | disclosed |
| EP-1615636-A1 | BICYCLIC COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004089366-A1 | BICYCLIC COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS | PFIZER JAPAN, INC. (JP) | 2004-10-21 | — | — | WO | disclosed |
| US-20040204409-A1 | Bicyclic compounds as NR2B receptor antagonists | ANDO KAZUO (JP) | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239797-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | KDM4E 2376/4885ALDH1A1 4692/4885LMNA 3201/4885 |
| US-20210253614-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CD73 | ENTPD5, NT5E, ENTPD1 | KDM4E 1503/4885ALDH1A1 868/4885LMNA 773/4885 |
| US-11274108-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | CSF1R, CSF3R, IL1RN | KDM4E 4101/4885ALDH1A1 1512/4885LMNA 4858/4885 |
| US-20160024079-A1 | Complement Factor B inhibitors and uses there of | CFB, CFH, CFD | KDM4E 2994/4885ALDH1A1 3348/4885LMNA 726/4885 |
| US-20040204409-A1 | Bicyclic compounds as NR2B receptor antagonists | GRIN1, GRIN2B, GRIN2A | KDM4E 2434/4885ALDH1A1 1871/4885LMNA 3923/4885 |
| US-12331068-B2 | Compositions and methods for inhibiting CD73 | ENTPD5, NT5E, ENTPD1 | KDM4E 1503/4885ALDH1A1 868/4885LMNA 773/4885 |
| US-20250092040-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | KDM4E 2376/4885ALDH1A1 4692/4885LMNA 3201/4885 |
| US-11999730-B1 | AKT1 modulators | AKT1S1, AKT1, AKT2 | KDM4E 2376/4885ALDH1A1 4692/4885LMNA 3201/4885 |
| US-20150191464-A1 | HETEROARYL SUBSTITUTED NICOTINAMIDE COMPOUNDS | IRAK4, IRAK3, IRAK2 | KDM4E 459/4885ALDH1A1 1647/4885LMNA 3020/4885 |
| US-20240174667-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | KDM4E 2376/4885ALDH1A1 4692/4885LMNA 3201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.